ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Large Academic Center Experience with Treatment of Suspected/Confirmed Kidney Transplant Active Antibody Mediated Rejection

J. T. Reece1, B. A. Steiner2, V. Bhoj1, N. Aqui1, R. D. Bloom3, J. Trofe-Clark4

1Transfusion Medicine Div, Univ of Pennsylvania, Philadelphia, PA, 2Pharmacy, Hosp of Univ of Pennsylvania, Philadelphia, PA, 3Renal Div, Univ of Pennsylvania, Philadelphia, PA, 4Pharmacy, Hospital of University of Pennsylvania, Philadelphia, PA

Meeting: 2020 American Transplant Congress

Abstract number: A-015

Keywords: Immunosuppression, Kidney transplantation, Rejection, Renal dysfunction

Session Information

Session Name: Poster Session A: Kidney Acute Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIG) are common active antibody mediated rejection (ABMR) treatments in kidney transplant recipients (KTRs), but with unclear benefits. The study purpose was to 1) describe diagnostic characteristics of KTRs undergoing treatment for suspected or confirmed active ABMR with TPE at our center and 2) to assess graft outcomes.

*Methods: We retrospectively reviewed HIV negative adult KTRs treated for suspected or confirmed active ABMR with TPE at least once at our center from 1/1/12-11/1/18. We reviewed biopsy reports and donor specific antibodies (DSAs) for all KTRs around time of treatment, and compared to active AMR Banff 2017 criteria. We evaluated DSAs at treatment initiation, and months 1,3,6,12,24 post-treatments, as well as graft survival data, collected until 10/1/19.

*Results: Fifty-nine KTRs received TPE and 96% received concurrent IVIG. By biopsy report review, less than half (43%) of KTRs treated for active ABMR met active ABMR Banff 2017 criteria, (19% had 1/3 criteria (DSA only), 15% had chronic ABMR, 14% met 2/3 active criteria, 5% met 0/3 active ABMR Banff criteria and 3% were indeterminate). Mean(SD) age of KTRs was 44 (±14) yrs, 35% were female, 51% were of black race and 19% were re-transplants. Of KTRs that met active ABMR Banff 2017 criteria, 42% had graft loss within 1 yr of treatment versus 18% who did not meet critera. [Table]. Of KTRs who had graft survival >3 yrs post-treatment only 27% met active ABMR Banff 2017 criteria. Only 23% of KTRs had graft loss <3 yrs post-transplant and 77% had graft survival for >3 yrs. Overall, 34% of KTRs had graft survival for >3 yrs post-treatment. [Figure].

*Conclusions: 1) Over 50% of KTRs who received active ABMR treatment (with at least one TPE), did not meet active ABMR Banff 2017 criteria. 2) Treated KTRs who meet active ABMR Banff 2017 criteria have significantly more graft loss compared to those who do not, suggesting criteria describe differences between these KTRs. 3) Studies are needed to define optimal interventions within populations.

Graft Survival by Diagnostic Features
Graft failure at > 3 yrs or no failure (%) Graft failure at <1 yr (%) Graft failure between >1 yr < 3 yrs (%)
0/3 Criteria for active ABMR (n = 3) 100 0 0
1/3 Criteria for active ABMR, (DSA only) (n = 11) 73 18 9
2/3 Criteria for active ABMR (n = 8) 63 25 13
3/3 Criteria for active ABMR (n = 26) 31 42 27
Chronic ABMR (n = 9) 56 22 22
Indeterminate findings (n = 2) 100 0 0

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Reece JT, Steiner BA, Bhoj V, Aqui N, Bloom RD, Trofe-Clark J. Large Academic Center Experience with Treatment of Suspected/Confirmed Kidney Transplant Active Antibody Mediated Rejection [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/large-academic-center-experience-with-treatment-of-suspected-confirmed-kidney-transplant-active-antibody-mediated-rejection/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences